Exelixis Inc

NASDAQ:EXEL

46.15

+1.85 (+4.18%)

4:41:40 PM EDT: $46.01 -0.14 (-0.30%)

Market Cap (Intraday)	13.11B
Current PE	20.37
Forward PE	17.35
2yr Forward PE	14.51

See more stats

Estimates Current Quarter

Revenue	$576.2 Million
Adjusted EPS	$0.64

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Exelixis Inc Stock, NASDAQ:EXEL

1851 Harbor Bay Parkway, Alameda, California 94502

United States of America

Phone: +1.650.837.7000

Number of Employees: 1147

http://www.exelixis.com

Description

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.